Santen Pharmaceutical Co., Ltd. clinical trials

The registry lists 94 studies whose lead sponsor is Santen Pharmaceutical Co., Ltd. or one of 8 companies grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 94. Browse all 94 →

• PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control GroupRecruitingNCT07235592

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• A Study in Chinese Patients With Acquired BlepharoptosisRecruitingNCT06683651Phase 3
• LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.RecruitingNCT06514612Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedNCT05376176Phase 2

  Sponsor listed in the registry: Santen Inc.

• Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.CompletedNCT06912802

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaActive, not recruitingNCT06666855Phase 3
• 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisCompletedNCT04701086Not applicable

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisActive, not recruitingNCT04685109Not applicable

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• A Pharmacokinetics (PK) Study in Healthy AdultsCompletedNCT06911216Early Phase 1
• 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)CompletedNCT04144413Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular HypertensionCompletedNCT05503901Phase 3
• Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaCompletedNCT05665387Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT04133311Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe KeratitisCompletedNCT03237936Phase 4

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• PRESERFLO® MicroShunt Extension StudyCompletedNCT04333433

  Sponsor listed in the registry: InnFocus Inc. · First submitted after InnFocus Inc. became part of Santen Pharmaceutical Co., Ltd.

• A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTCompletedNCT02981446Phase 3
• Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males VolunteersCompletedNCT05905653Phase 1
• A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT05495061Phase 3
• LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the EyeTerminatedNCT03711929Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyCompletedNCT03691649Phase 3

  Sponsor listed in the registry: Santen Inc.

• DE-117 Spectrum 5 StudyCompletedNCT03697811Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyCompletedNCT03691662Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular HypertensionCompletedNCT03822559Phase 3
• Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04742283Phase 2

  Sponsor listed in the registry: Santen Inc.

• Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World SettingCompletedNCT04828057

  Sponsor listed in the registry: Santen Pharmaceutical (Taiwan) Co., LTD

• InnFocus MicroShunt Versus Trabeculectomy StudyCompletedNCT01881425Not applicable

  Sponsor listed in the registry: InnFocus Inc. · First submitted before InnFocus Inc. became part of Santen Pharmaceutical Co., Ltd.

• Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal KeratoconjunctivitisCompletedNCT01751126Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag IsopropylStatus unknownNCT05279716Phase 4

  Sponsor listed in the registry: Santen Pharmaceutical Asia Pte. Ltd.

• Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)CompletedNCT00328653Phase 2/3

  Sponsor listed in the registry: Santen SAS · First submitted before Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Clinical Study of the Safety and Performance of the Miami InnFocus Drainage Implant to Relieve Glaucoma SymptomsCompletedNCT00772330Not applicable

  Sponsor listed in the registry: InnFocus Inc. · First submitted before InnFocus Inc. became part of Santen Pharmaceutical Co., Ltd.

• Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsCompletedNCT03211234Phase 2

  Sponsor listed in the registry: Santen Inc.

• Post Market Study of the InnFocus MicroShuntCompletedNCT02177123Not applicable

  Sponsor listed in the registry: InnFocus Inc. · First submitted before InnFocus Inc. became part of Santen Pharmaceutical Co., Ltd.

• Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage ImplantCompletedNCT01563237Not applicable

  Sponsor listed in the registry: InnFocus Inc. · First submitted before InnFocus Inc. became part of Santen Pharmaceutical Co., Ltd.

• Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)CompletedNCT04737928Not applicable

  Sponsor listed in the registry: Santen Pharmaceutical (Taiwan) Co., LTD

• Prevalence of Ocular Surface Disease in Malaysian Glaucoma PatientsStatus unknownNCT04609345

  Sponsor listed in the registry: Santen Pharma Malaysia Sdn Bhd

• A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel StudyCompletedNCT03216902Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)CompletedNCT03329638Phase 2
• Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6CompletedNCT03858894Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development ProgramCompletedNCT02251938Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular DegenerationCompletedNCT02555306Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Study Assessing Double-masked Uveitis TreatmentCompletedNCT01358266Phase 3

  Sponsor listed in the registry: Santen Inc.

• Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye DiseaseCompletedNCT03216096Phase 1
• Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT01868126Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02022501Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedNCT01654484Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT02179008Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02401945Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract SurgeryCompletedNCT02888210Phase 3
• A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE StudyCompletedNCT02822729Phase 3
• A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-CompletedNCT02623738Phase 2/3